Glove_box_At211

SGS4030AT model for containment Atley C100 Example of application ----------> Atley Solutions:  
The Atley C100 module allows for an automated, standardized and reproducible production of At-211 radiopharmaceuticals, and is controlled by clinically validated software. 

Atley Solutions is a global leader in commercial products and services for the development and manufacturing of radiopharmaceuticals based on At-211. The company's first product, the Atley C100 module, is the first in the world to allow for scalable, standardized and reproducible manufacturing of At-211 radiolabeled compounds. Atley is committed to being a driving force in developing industry-wide solutions and infrastructure to unlock the potential of At-211 radiopharmaceuticals.

                                                                                                                 SGS303AT model with airlock positioned under the work area
airlock  with hinged door, square in shape, and a external front door for material introduction. (The useful passage dimensions are 200x200x200 mm).
The airlock is equipped with a pneumatic lifting device , static gaskets and pneumatic interlocking device to prevent the simultaneous opening of the doors.

The use of radiopharmaceuticals to selectively treat cancer cells, including micrometastases, is emerging as a new frontier in oncology.
However, existing radiopharmaceutical supply chains are often under strain, posing a risk to patient care, clinical trials, and ongoing drug development.
Astatine-211 is an alpha-emitting radioisotope used in cancer-fighting medical applications called targeted alpha therapy (TAT). The radioisotope has a 7.2-hour half-life and clean decay properties, requiring new approaches for implementation within both laboratory and clinical environments. Today, astatine-211 usage is generally limited to select geographic areas near academic and medical centers where the isotope is produced in small batches.

There is real hope  that in the near future, At-211 will be available in high quantities and in various areas of the world:  synergies of researchers and highly specialized companies are now working towards this goal for the benefit of patients all over the world